Otsuka Pharma May Acquire Injectibles Biz Of Claris Lifesciences
by Charmi Gutka
@Claris_Lifesciences is planning to sell its injectibles business and it is in preliminary talks with Japanese Pharma firm - Otsuka Pharma for the same.
IDFC and Barclays are the bankers to the deal, ET stated.
This news comes after the announcement by Strides Arcolabs to put up its injectable-drugs unit, @Agila_Specialties Private Limited for sale.
Ahmedabad based, Claris Lifesciences offers injectibles in various therapeutic segments including anesthesia, critical care, anti-infectives, renal care, infusion therapy, parenteral nutrition and oncology.
It has presence in 91 countries across Latin America, Europe, Gulf, Africa, CIS, Central Asia and Asia- Pacific. Last month, Mitsui of Japan, through its healthcare arm, was plnning to invest R250 Cr in Claris.
Hyderabad-based CVR Group unit Navayuga Power may sell stake in its power assets to Toshiba, Sumitomo, Mitsubishi & GDF Suez. The deal Value expected to be in between INR 13,800 to 14,400 Mn for equity stake 49 to 51%.
DealCurry tracks financial and corporate markets for events, interprets and integrates the information in our platform, providing premium data, news and analytics. DealCurry provides comprehensive coverage of the capital markets through an intuitive, user-friendly interface.